EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

• Status: Not yet recruiting
• Trial end date: 2027-01-16
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Collaborator: Colorado Prevention Center
• Treatments: Evolocumab

Criteria

Inclusion Criteria:

• Age greater than or equal to 18 years

• Hospitalized for primary reason of NSTEMI or STEMI due to presumed atherosclerotic disease

Exclusion Criteria:

• Participants requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening

• Participants with elevated biomarkers of myocardial injury due to secondary/nonatherosclerotic etiology (eg, sepsis, atrial fibrillation, vasospasm, decompensated heart failure, uncontrolled hypertension)